Clinical Trial Update: Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating empagliflozin for SIADH-related hyponatremia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuresis

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2, Phase 3 | Status: COMPLETED